ProfileGDS5678 / 1449025_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 87% 84% 92% 83% 90% 84% 81% 86% 72% 76% 80% 82% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8117388
GSM967853U87-EV human glioblastoma xenograft - Control 26.7675787
GSM967854U87-EV human glioblastoma xenograft - Control 36.2386884
GSM967855U87-EV human glioblastoma xenograft - Control 47.8535692
GSM967856U87-EV human glioblastoma xenograft - Control 56.0641683
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9775590
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0282884
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7866181
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4446486
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6688672
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0210676
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6464180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8937982
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1790177